Interim / Quarterly Report • Aug 8, 2016
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
| 1.4- 30.6.2016 |
1.4- 30.6.2015 |
Change-% | 1.1.- 30.6.2016 |
1.1- 30.6.2015 |
Change-% | |
|---|---|---|---|---|---|---|
| Net sales, Group | 5.8 | 4.9 | 19.7 | 11.0 | 9.5 | 16.4 |
| Operating profit, Group | 1.7 | 1.5 | 12.7 | 3.0 | 2.9 | 3.5 |
| Net sales, Health Tech | 5.8 | 4.9 | 19.7 | 11.0 | 9.5 | 16.4 |
| Operating profit, Health Tech |
2.1 | 1.9 | 12.9 | 3.7 | 3.6 | 4.2 |
| Undiluted earnings per share |
0.18 | 0.14 | 28.6 | 0.30 | 0.30 | 0.0 |
| Cash flow from operating activities |
1.2 | 0.9 | 29.6 | 1.2 | 4.0 | -70.8 |
| 30 June 2016 |
30 June 2015 |
Change, %-point |
||||
| Equity ratio-% | 79.3 | 79.0 | 0.3 | |||
| Gearing-% | -24.3 | -38.6 | 14.3 |
Net sales growth is expected to remain strong. Profitability is expected to remain at a healthy level despite growth investments.
"Our performance, both in terms of numbers and development projects, developed as planned, with both EMEA and Latin America generating strong sales. Sales of the Icare ic100 tonometer launched in Europe at the beginning of the year took off well. In April, a sales permit was granted for the Icare ic100 in the United States, and product launch is currently in progress. We expect this new-generation product to accelerate sales in the US markets towards the year-end.
Icare is preparing to file a new sales license application to the FDA after the completion of the feasibility study. The new application is expected to be filed during 2016 as planned.
Probe sales continued to grow following growth in device sales and increasingly active use of the devices.
Development projects involving skin cancer and asthma-related product concepts are moving forward as planned. A prototype of a skin cancer diagnostic device is currently being tested. I feel very confident about the future of these product concepts."
Revenio Group's net sales grew to EUR 11.0 (9.5) million, an increase of 16.4 per cent. Positive sales trends especially in China, major European countries, Japan, Australia, Canada and Latin America contributed to net sales growth. Individual countries showing particularly strong sales was the United Kingdom.
Revenio Group's operating profit for the period amounted to EUR 3.0 (2.9) million, showing an increase of 3.5 per cent. Operating profit accounted for 27.3 per cent of net sales. The net sales development should be assessed against planned human resource investments required for the global sales launch of Icare HOME and Icare ic100 tonometers, and for the asthma and skin cancer product development projects. Salary costs in the review period were higher than a year earlier, but are expected to normalize during the last quarter of the year. Most of the recruited employees joined the company in late 2015, which is reflected in the salary costs for the review period. Recruitment focused on sales and marketing and product development personnel. The increase in material and service costs attributed to changes in the product mix.
Sales of the new generation Icare ic100 tonometer took off well in Europe. US market launch took place on April 20, 2016 once the FDA had granted the product a sales permit in the United States. Icare ic100 tonometers were delivered to customers during the review period. Excellent feedback was received from users in Europe and in the United States. As expected, the product generation replacement from Icare TA01 to Icare ic100 caused a slight delay in US sales as products are being delivered to independent sales representatives and they are provided with relevant sales training. Although we expect the Icare ic100 to gradually replace the Icare TA01 tonometer, which was launched in 2003, we believe that the TA01 will continue to generate healthy sales for several years, particularly in developing countries. Icare ic100 registrations are already under way among others in Japan and Canada.
The United States Food and Drug Administration FDA did not approve the sales license application for Icare HOME in March. Icare has launched design and implementation of a further feasibility study. According to the company's view, the new application is ready to be filed during the current year and the work is proceeding as planned.
Probe sales showed steady growth and were 32.5 per cent higher than a year earlier. Probes accounted for almost 28 per cent of total sales.
Revenio Research Oy's development projects on product concepts related to skin cancer and asthma are progressing as planned. An application for a CE marking for the asthma product has been submitted. The CE marking will allow the start of sales and marketing as well as broader clinical studies in Finland and rest of Europe. Test measurements with the prototype of a device designed for skin cancer diagnostics has been started during the spring in Finland and internationally.
Oscare Medical has signed a major sales contract with a Nordic pharmacy chain in Norway, and the first product training session has been held. Test campaigns have been organized in a German health product chain. The expansion of the European distributor network is currently under way. In Finland, Oscare's bone sonometer earned publicity in an event hosted by Luustoliitto (Finnish bone health association) at the Finnish Parliament. At the event, held in May, more than 100 Members of Parliament and other officials were analyzed with the sonometer.
Revenio Group's consolidated net sales from continuing operations for the period January 1–June 30, 2016 totaled EUR 11.0 (9.5) million; an increase of 16.4 per cent. Profit before taxes totaled EUR 3.0 (2.9) million, up by 4.4 per cent on the previous year. Profit before taxes totaled 27.6 per cent of net sales.
Consolidated operating profit in January-June totaled EUR 3.0 (2.9) million, up 3.5 per cent. Undiluted earnings per share from continuing operations came to EUR 0.18 (EUR 0.14). Equity per share was EUR 1.54 (1.60).
The Revenio Health Tech segment's net sales showed a year-on-year increase of 16.4 per cent to EUR 11.0 (9.5) million, while its operating profit was up by 4.2 per cent to EUR 3.7 (3.6) million.
Exchange rate fluctuations had no major effect on the Group's net sales or operating profit.
The consolidated balance sheet total stood at EUR 14.7 (16.0) million on June 30, 2016. Consolidated shareholders' equity amounted to EUR 11.7 (12.9) million. At the end of the reporting period, interest-bearing liabilities amounted to EUR 0.4 (0.6) million and gearing was - 24.3 per cent (-38.6). The consolidated equity ratio was 79.3 per cent (79.0). The Group's liquid assets amounted to EUR 3.3 (6.2) million on June 30, 2016.
Despite dividend payment and investments in the Health Tech segment's future growth, the Group's financial position remained stable during the reporting period. On June 30, 2016, the balance sheet showed goodwill of EUR 1.2 (1.2) million.
Cash flow from operations totaled EUR 1.7 (4.0) million. The discontinued operations had a significant impact on the Group's cash flow during the period. The Group's purchases of PPE and intangible assets totaled EUR 0.9 (1.0) million. Investments focused mainly on product development.
The annualized average number of personnel employed by the Group in continuing operations during the period amounted to 41 (30). The number of personnel grew by 11 during the period, to 41 (30).
In May, Revenio Group Plc.'s Board of Directors appointed Timo Hildén, M. Sc., (born 1959) as the new Group CEO, effective on January 1st, 2017. Hildén has been the CEO of Revenio Group's subsidiary Icare Finland since April 2012. Hildén was also appointed as the Segment Director of Revenio Health Tech as of May 16th, 2016.
At the same time, Revenio announced that the Group's long-standing CEO Olli-Pekka Salovaara would leave his position on January 1st, 2017 after a transition period and that he would continue to serve as a full-time Executive Chairman of Icare USA Inc.'s Board of Directors.
The Management Team of Revenio Group was expanded, and as of June 1st, 2016 members include Revenio Group Plc's CEO Olli-Pekka Salovaara (until December 31, 2016), Icare Finland Ltd's CEO and Segment Director of Revenio Health Tech Timo Hildén, Revenio Group Plc's CFO Robin Pulkkinen, Sales and Marketing Director Tomi Karvo, Revenio Research Oy's R&D Director Ari Kukkonen and, as a new member, Icare Finland Ltd's Operations Director Ari Isomäki. Tiina Olkkonen will attend Management Team meetings as an external communication specialist and Management Team secretary. In addition, an Extended Management Team was established on June 1st, 2016, having quarterly meeting and consisting of Management Team members and John Floyd, the CEO of Icare USA Inc.
| Average no. of employees by segment | ||||||||
|---|---|---|---|---|---|---|---|---|
| 30 June 2016 | 30 June 2015 | Change | ||||||
| Revenio Health Tech | 36 | 28 | 8 | |||||
| Parent Company | 5 | 2 | 3 | |||||
| Group Total | 41 | 30 | 11 |
Wages, salaries, and other remuneration paid during the period totaled EUR 1.5 million.
On June 30, 2016, the Revenio Group Corporation's fully paid-up share capital registered with the Trade Register totaled EUR 5,246,380.35 and the number of shares 7,979,406.
During the review period, the number of shares increased by 32,978 following subscriptions made on the basis of the 2007 stock option scheme. Series 2007C option rights were used to subscribe for 32,978 shares. The subscription period for Series 2007C options ended on May 1, 2016.
The company has one class of share, and all shares confer the same voting rights and an equal right to dividends and the company's funds. On June 30, 2016, the President & CEO, members of the Board of Directors and their closely related parties held 13.4 per cent, or 1,070,582 of the company's shares, and 5.0 per cent of the option rights.
The Annual General Meeting of Revenio Group Corporation held on March 15, 2016 decided that 40 per cent of Board members' emoluments will be settled in the form of company shares. Accordingly, as announced on May 27, 2016, Revenio Group Corporation transferred to Board members a total of 2,455 shares as follows: A total of 819 shares were transferred to Board chairman Pekka Tammela, as a result of which his ownership of instruments issued by the company amounts to 26,888 shares. A total of 409 shares were transferred to Board member Ari Kohonen, as a result of which his personal and his related parties' ownership of instruments issued by the company amounts to 342,269 shares. A total of 409 shares were transferred to Board member Pekka Rönkä, as a result of which his ownership of instruments issued by the company amounts to 1,210 shares. A total of 409 shares were transferred to Board member Kyösti Kakkonen, as a result of which his personal and his related parties' ownership of instruments issued by the company amounts to 592,719 shares. A total of 409 shares were transferred to
Board member Ann-Christine Sundell, as a result of which her ownership of instruments issued by the company amounts to 809 shares. As a result of these transfers, the share-based Board member fees have been settled in full. After the transfers, Revenio Group Corporation holds 4,959 of its own shares.
In late 2015, the employees of Revenio Group established a personnel fund, into which any bonuses earned by employees working in Finland on the basis of incentive schemes can be paid. All employees are included in the performance-based bonus scheme. During the review period, the personnel fund acquired nearly 7,000 Revenio shares using bonuses funded by employees.
On February 25, 2016, the Board of Directors of Revenio Group Corporation decided to start purchasing the company's own shares, a maximum of seven thousand, (7,000) based on an authorization granted at the AGM of March 19, 2015. During the specified period, a total of 6,860 shares were purchased for EUR 165,408.03. At the end of the review period, on June 30, 2016, Revenio Group Corporation held 4,959 of its own shares.
Shares were purchased by using the invested non-restricted equity fund.
Based on the share issue authorization granted by the Annual General Meeting of March 19, 2015, Revenio Group Corporation's Board of Directors decided, on August 10, 2015, to implement a new option scheme comprising a maximum of 150,000 option rights. One option right entitles its holder to subscribe for one share. New shares subscribed for via the option program entitle the holder to a dividend from the year of subscription onwards. The option rights will be allocated, as determined by the Board of Directors, to key personnel employed or to be employed by the Revenio Group in accordance with the terms and conditions of the option scheme.
These option rights are divided into three series: Series A (50,000), Series B (50,000) and Series C (50,000). The subscription periods for options are as follows: Series A: May 31, 2017–May 31, 2019; Series B: May 31, 2018–May 31, 2020; and Series C: May 31, 2019–May 31, 2021. The share subscription price for Series A options will be the trade-weighted average price of Revenio share quoted on Nasdaq Helsinki Oy during the period September 1 – October 15, 2015 plus 15 per cent; for Series B options the trade-weighted average price of Revenio share quoted on Nasdaq Helsinki Oy during the period September 1 – October 15, 2016 plus 15 per cent; and for Series C options the trade-weighted average price of Revenio share quoted on Nasdaq Helsinki Oy during the period September 1 – October 15, 2017 plus 15 per cent. During the review period, 41,000 series A options rights were issued to personnel. The subscription price for series A shares was EUR 26.94.
During January 1–June 30, 2016, the Revenio Group Corporation's share turnover on the Nasdaq Helsinki exchange totaled EUR 30.4 (27.1) million, representing 1.2 (1.4) million shares or 15.4 (17.9) per cent of all shares outstanding. The highest trading price was EUR 29.49 (23.15) and the lowest EUR 21.53 (14.37). At the end of the period, the closing price was EUR 24.51 (19.37), and the average share price for the period was EUR 24.81 (18.54). The Revenio Group Corporation's market value stood at EUR 195.6 (153.7) million on June 30, 2016.
| January-June | Volume, pcs | Value | High, eur | Low, eur | Average | Last, eur | ||
|---|---|---|---|---|---|---|---|---|
| 2016 | total, eur | price, eur | ||||||
| REG1V | 1,226,320 | 30,430,164 | 29.49 | 21.53 | 24.81 | 24.51 |
| 30.6.2016 | 31.12.2015 | |
|---|---|---|
| Market cap, eur | 195,575,241 | 227,347,305 |
| Shareholders | 7,603 | 6,507 |
The Revenio Group's major business risks and uncertainty factors are presented in the financial statement bulletin released on February 15, 2016, available at www.revenio.fi.
The Revenio Group's risks are divided into strategic, operational, trade cycle, accident, and financial risks. Internal auditing is conducted by Ernst & Young Oy.
The Group's strategic risks include competition in all sectors, the threat posed by new competing products, and any other actions of the company's rivals that may affect the competitive situation. Another strategic risk is related to the ability to succeed in R&D activities and to maintain a competitive product mix. Strategic risks in the Group's segments requiring special expertise are also associated with the successful management and development of key human resources and the management of the subcontractor and supplier network Corporate acquisitions and the purchase of assets with growth potential related to health tech are part of Group strategy. The success of these acquisitions has a significant impact on the reaching of growth and profitability targets. Acquisitions may also change the Group's risk profile. Strategic risks and the need for action are regularly assessed and are monitored in connection with day-to-day management, monthly Group reporting, and regular strategy updates.
Operational risks are associated with the retention and development of major customers, the operations of the distribution network and success in extending the customer base and markets. In the Revenio Health Tech segment especially, operational risks include factors related to expansion into new markets, such as various countries' regulation of sales licenses for medical instruments imposed at national level and the related official decisions concerning the health care market. Success in health tech R&D projects launched in accordance with the strategy can also be classified as an operational risk. The operational risks related to the manufacture, product development, and production control of medical instruments are estimated to be higher than average in the Revenio Health Tech segment, because of that sector's requirements concerning quality.
Accident risks are covered by insurance. Property and business interruption insurance provide protection against risks in these areas. The business pursued is covered by international liability insurance.
Financial risks can be further categorized into credit, interest-rate, liquidity, and foreign exchange risks. To manage credit loss risks, the Group has taken out credit insurance covering all companies in the Group. Every month, and more frequently if necessary, the Board, in its meetings, assesses matters related to financial issues. If required, the Board provides decisions and guidelines for the management of financial risks concerning interest-rate and currency hedging, for instance. The liquidity risk can be affected by the availability of external financing, the development of the Group's credit standing, the trend in business operations and changes in the payment behavior of customers. Liquidity risks are monitored using cash forecasts, which are drawn up for periods of 12 months at most at a time.
Decisions by the Annual General Meeting of Revenio Group Corporation on March 15, 2016:
The AGM confirmed the company's financial statements for the financial year January 1 – December 31, 2015, and discharged the members of the Board of Directors and the Managing Director from liability.
The Annual General Meeting decided to elect five members to the Board of Directors. Rolf Fryckman, Ari Kohonen, Pekka Rönkä, Kyösti Kakkonen and Pekka Tammela were re-elected, while Ann-Christine Sundell was elected as a new member. At its organization meeting, held after the Annual General Meeting, the Board of Directors re-elected Pekka Tammela as Chairman of the Board.
The AGM decided that the Chairman of the Board be entitled to an annual emolument of EUR 48,000 and the other Board members to an annual emolument of EUR 24,000.
A total of 40 percent of Board members' emoluments will be paid out in the form of company shares, while 60 percent will comprise a monetary payment.
The AGM re-appointed PricewaterhouseCoopers Oy, Authorized Public Accountants, as the company's auditors with Samuli Perälä, Authorized Public Accountant, as principal auditor. The AGM decided to compensate the auditors upon the presentation of a reasonable invoice.
The AGM decided to accept the Board's proposal on profit distribution, according to which the parent company's profit for the financial period, EUR 5,759,744.54, will be added to retained earnings, and a dividend of EUR 0.70 per share will be paid. Dividends will be paid to shareholders who have been registered in the company's shareholder register, maintained by Euroclear Finland Ltd, by the dividend record date March 17, 2016. The dividend payment date was March 24, 2016.
The AGM authorized the Board to make the decision to buy back a maximum of 795,392 of the company's own shares in one or several tranches using the Company's non-restricted equity capital. The company may buy back shares in order to develop its capital structure, in order to finance and implement any corporate acquisitions or other transactions, and to implement sharebased incentive plans or otherwise transfer or cancel them.
The company may buy back shares in public trading on marketplaces whose rules and regulations allow the Company to trade in its own shares. In such a case, the Company buys back shares through a directed purchase, that is, in a proportion other than its shareholders' holdings in Company shares, with the consideration for the shares based on their publicly quoted market price, in such a manner that the minimum price of the purchased shares equals the lowest market price quoted in public trading during the authorization period, and, similarly, their highest price equals the highest market price quoted in public trading during that period.
This authorization will be valid until April 30, 2017. This authorization supersedes the buyback authorization granted at the AGM of March 19, 2015.
The AGM authorized the Board of Directors to decide on the issuance, following the approval of the reverse share split, of a maximum of 795,392 shares or to grant special rights (including stock options) entitling holders to shares as referred to in Chapter 10 Section 1 of the Limited Liability Companies Act, in one or several tranches.
This authorization was granted for the purpose of financing and implementing any prospective corporate acquisitions or other transactions, implementing the company's share-based incentive schemes, or for other purposes determined by the Board.
The authorization grants the Board the right to decide on all terms and conditions governing the said share issue and the granting of special rights, including the subscribers or grantees of the special rights, and the consideration payable. It also includes the right to waive shareholders' preemptive subscription rights, and covers the issue of new shares and the transfer of any shares that may be held by the company.
The Board proposes that the authorization remain valid until April 30, 2017. This authorization supersedes the authorization to decide on an issuance of new shares and on the granting of special rights giving entitlement to shares granted at the AGM of March 19, 2015.
There have been no major events since the end of the review period.
This interim report has been prepared in compliance with IAS 34 Interim Financial Reporting. In preparing this interim report, Revenio Group Corporation has applied the same accounting principles as in its financial statements for 2015, with the exception that, as of January 1, 2016, the Group has implemented the new or revised standards and IFRIC interpretations published by IASB and specified in the Group's accounting principles.
The figures are unaudited.
The Interim Report Q1-Q3 will be published on Monday, October 31, 2016.
Due to an amendment to the Securities Market Act, which came into force on November 26, 2015, the descriptive sections of Revenio's Interim Reports Q1/2016 and Q1-Q3/2016 will be shorter and more concise than before. The table sections will be reported in accordance with previous practices.
| 1- | |||||
|---|---|---|---|---|---|
| Group key figures and ratios (MEUR) | 1-6/2016 | 4-6/2016 | 1-6/2015 | 4-6/2015 | 12/2015 |
| Net sales, continuing operations | 11.0 | 5.8 | 9.5 | 4.9 | 20.3 |
| Ebitda, continuing operations | 3.3 | 1.8 | 3.1 | 1.6 | 6.3 |
| Ebitda-%, continuing operations | 30.3 | 31.6 | 33.3 | 33.1 | 31.1 |
| Operating profit, continuing operations | 3.0 | 1.7 | 2.9 | 1.5 | 5.8 |
| Operating profit-%, continuing operations | 27.3 | 28.7 | 31.0 | 31.0 | 28.4 |
| Pre-tax profit, continuing operations | 3.0 | 1.7 | 2.9 | 1.4 | 5.9 |
| Pre-tax profit-%, continuing operations | 27.6 | 29.5 | 30.1 | 26.6 | 29.2 |
| Net profit from discontinued operations | 0.0 | 0.0 | 2.0 | 1.7 | 1.9 |
| Net profit, continuing operations | 2.3 | 1.4 | 2.4 | 1.2 | 4.6 |
| Net profit-%, continuing operations | 21.3 | 24.0 | 24.4 | 22.2 | 22.7 |
| Gross capital expenditure | 0.8 | 0.5 | 1.0 | 0.5 | 2.3 |
| Gross capital expenditure-% | 7.0 | 8.5 | 10.4 | 9.8 | 11.2 |
| R&D costs | 0.9 | 0.5 | 0.5 | 0.1 | 0.9 |
| R&D costs-% from net sales | 8.3 | 8.5 | 5.5 | 2.4 | 4.5 |
| Gearing-% | -24.3 | -24.3 | -38.6 | -38.6 | -48.3 |
| Equity ratio-% | 79.3 | 79.3 | 79.0 | 79.0 | 81.6 |
| Return on investment-% (ROI) | 43.1 | 48.6 | 34.4 | 39.3 | 42.1 |
| Return on equity-% (ROE) | 35.2 | 41.9 | 46.6 | 43.3 | 33.9 |
| Undiluted earnings per share, EUR, continuing | |||||
| operations | 0.30 | 0.18 | 0.30 | 0.14 | 0.61 |
| Diluted Earnings per share, EUR, continuing | |||||
| operations | 0.30 | 0.18 | 0.30 | 0.15 | 0.61 |
| Equity per share, EUR | 1.54 | 1.54 | 1.60 | 1.60 | 1.52 |
| Average no. of employees, continuing | |||||
| operations | 41 | 41 | 30 | 29 | 37 |
| Cash flow from operating activities | 1.7 | 1.2 | 4.0 | 0.9 | 4.9 |
| Cash flow from discontinued activities | 0.0 | 0.0 | 0.1 | -0.2 | 2.0 |
| Cash flow from investing activities | -0.8 | -0.5 | 1.8 | 1.1 | 1.3 |
| Net cash used in financing activities | -5.9 | -0.9 | -3.8 | -0.7 | -4.1 |
| Total cash flow | -5.0 | -0.2 | 2.1 | 1.1 | 4.2 |
| NET SALES | 11.0 | 9.5 | 20.3 |
|---|---|---|---|
| Other operating income | 0.0 | 0.0 | 0.1 |
| Materials and services | -3.1 | -2.4 | -5.3 |
| Employee benefits | -2.3 | -1.5 | -3.9 |
| Depreciation/amortization | -0.3 | -0.2 | -0.5 |
| Other operating expenses | -2.3 | -2.4 | -4.8 |
| OPERATING PROFIT, CONTINUING OPERATIONS | 3.0 | 2.9 | 5.8 |
| Financial income and expenses (net) | 0.0 | 0.0 | 0.1 |
| PRE-TAX PROFIT, CONTINUING OPERATIONS | 3.0 | 2.9 | 5.9 |
|---|---|---|---|
| Income tax expense | -0.7 | -0.5 | -1.3 |
| Net profit from continuing operations | 2.3 | 2.4 | 4.6 |
| Net profit from discontinued operations | 0.0 | 2.0 | 1.9 |
| NET PROFIT | 2.4 | 4.3 | 6.5 |
| Other comprehensive income items | 0.0 | 0.0 | 0.0 |
| Income tax expense for comprehensive income | 0.0 | 0.0 | 0.0 |
| Other comprehensive income items | |||
| after taxes | 0.0 | 0.0 | 0.0 |
| TOTAL COMPREHENSIVE INCOME | 2.4 | 4.3 | 6.5 |
| Net profit attributable to: | |||
| Parent company shareholders | 2.5 | 4.4 | 6.8 |
| Non-controlling interests | -0.1 | -0.1 | -0.3 |
| Total comprehensive income attributable to: | |||
| Parent company shareholders | 2.5 | 4.4 | 6.8 |
| Non-controlling interests | -0.1 | -0.1 | -0.3 |
| Earnings per share, undiluted, EUR, continuing operations | 0.30 | 0.30 | 0.61 |
| Earnings per share, diluted, EUR, continuing operations | 0.30 | 0.30 | 0.61 |
| Consolidated comprehensive income statement (MEUR) | 4-6/2016 | 4-6/2015 |
|---|---|---|
| NET SALES | 5.8 | 4.9 |
| Other operating income | 0.0 | 0.0 |
| Materials and services | -1.7 | -1.2 |
| Employee benefits | -1.1 | -0.8 |
| Depreciation/amortization | -0.2 | -0.1 |
| Other operating expenses | -1.1 | -1.2 |
| OPERATING PROFIT, CONTINUING OPERATIONS | 1.7 | 1.5 |
| Financial income and expenses (net) | 0.0 | -0.1 |
| PRE-TAX PROFIT, CONTINUING OPERATIONS | 1.7 | 1.4 |
| Income tax expense | -0.3 | -0.2 |
| Net profit from continuing operations | 1.4 | 1.1 |
| Net profit from discontinued operations | 0.0 | 1.7 |
| NET PROFIT | 1.4 | 2.8 |
| Other comprehensive income items | 0.0 | 0.0 |
| Income tax expense for comprehensive income | 0.0 | 0.0 |
| Other comprehensive income items | ||
| after taxes | 0.0 | 0.0 |
| TOTAL COMPREHENSIVE INCOME | 1.4 | 2.8 |
| Net profit attributable to: | ||
| Parent company shareholders | 1.4 | 2.8 |
| Total comprehensive income attributable to: | ||
| Parent company shareholders | 1.4 | 2.8 |
| Consolidated balance sheet (MEUR) |
30 Jun 2016 | 30 Jun 2015 | 31 Dec 2015 |
|---|---|---|---|
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Property. plant and equipment | 0.9 | 0.7 | 0.7 |
| Goodwill | 1.2 | 1.2 | 1.2 |
| Intangible assets | 4.0 | 3.2 | 3.7 |
| Deferred tax assets | 0.3 | 0.4 | 0.2 |
| TOTAL NON-CURRENT ASSETS | 6.4 | 5.5 | 5.8 |
| CURRENT ASSETS | |||
| Inventories | 2.3 | 1.5 | 1.8 |
| Trade and other receivables | 2.8 | 2.7 | 2.6 |
| Cash and cash equivalents | 3.3 | 6.2 | 8.3 |
| TOTAL CURRENT ASSETS | 8.4 | 10.5 | 12.6 |
| Non-current assets held | |||
| for sale | 0.0 | 0.0 | 0.0 |
| TOTAL ASSETS | 14.7 | 16.0 | 18.4 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||
| SHAREHOLDERS' EQUITY | |||
| Share capital | 5.3 | 5.3 | 5.3 |
| Share premium | 2.4 | 2.4 | 2.4 |
| Fair value reserve | 0.3 | 0.3 | 0.3 |
| Invested unrestricted capital reserve | 4.5 | 4.6 | 4.6 |
| Retained earnings/loss | -0.2 | 0.2 | 2.8 |
| TOTAL EQUITY. attributable to holders | |||
| of parent company equity | 12.3 | 13.0 | 15.5 |
| Non-controlling interests | -0.6 | -0.1 | -0.5 |
| TOTAL SHAREHOLDERS' EQUITY | 11.7 | 12.9 | 15.0 |
| LIABILITIES | |||
| NON-CURRENT LIABILITIES | |||
| Deferred tax liabilities | 0.0 | 0.0 | 0.0 |
| Provisions | 0.0 | 0.1 | 0.0 |
| Financial liabilities | 0.6 | 0.5 | 0.5 |
| TOTAL LONG-TERM LIABILITIES | 0.6 | 0.7 | 0.5 |
| CURRENT LIABILITIES | |||
| Trade and other payables | 2.3 | 1.9 | 2.5 |
| Financial liabilities | 0.2 | 0.6 | 0.4 |
| TOTAL SHORT-TERM LIABILITIES | 2.5 | 2.5 | 2.9 |
| Long-term liabilities held | |||
| for sale | 0.0 | 0.0 | 0.0 |
| TOTAL LIABILITIES | 3.1 | 3.1 | 3.4 |
| TOTAL LIABILITIES AND | |||
| SHAREHOLDERS' EQUITY | 14.7 | 16.0 | 18.4 |
| Share | Share | Other | Retained | Non controlling |
Total | ||
|---|---|---|---|---|---|---|---|
| capital | Premium | Reserves | Earnings | Total | interests | Equity | |
| Balance 1 Jan 2016 | 5.3 | 2.4 | 4.9 | 2.8 | 15.5 | -0.5 | 15.0 |
| Dividend distribution | 0.0 | 0.0 | 0.0 | -5.6 | -5.6 | 0.0 | -5.6 |
| Acquisition of own shares | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | 0.0 | -0.2 |
| Other direct entries to retained earnings | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 |
| Used option rights | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total comprehensive income | 0.0 | 0.0 | 0.0 | 2.5 | 2.5 | -0.1 | 2.4 |
| Balance 30 Jun 2016 | 5.3 | 2.4 | 4.8 | -0.2 | 12.3 | -0.6 | 11.7 |
| Share | Share | Other | Retained | Non controlling |
Total | ||
|---|---|---|---|---|---|---|---|
| capital | Premium | Reserves | Earnings | Total | interests | Equity | |
| Balance 1 Jan 2015 | 5.3 | 2.4 | 4.9 | -0.4 | 12.3 | -0.2 | 12.1 |
| Dividend distribution | 0.0 | 0.0 | 0.0 | -3.6 | -3.6 | 0.0 | -3.6 |
| Used option rights | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total comprehensive income | 0.0 | 0.0 | 0.0 | 4.4 | 4.4 | -0.1 | 4.3 |
| Balance 30 Jun 2015 | 5.3 | 2.4 | 4.9 | 0.5 | 13.2 | -0.3 | 12.8 |
| Consolidated cash flow statement (MEUR) | 1-6/2016 | 1-6/2015 | 1-12/2015 |
|---|---|---|---|
| Net profit | 2.4 | 4.3 | 4.6 |
| Adjustments to net profit | 0.4 | 0.4 | 0.4 |
| Taxes | 0.7 | 0.5 | 1.3 |
| Change in working capital | -1.4 | -0.9 | -0.5 |
| Interest paid | 0.0 | 0.0 | -0.3 |
| Interest received | 0.0 | 0.0 | 0.4 |
| Taxes paid | -0.3 | -0.3 | -1.1 |
| CASH FLOW FROM OPERATING ACTIVITIES | 1.7 | 4.0 | 4.9 |
| Cash flow from discontinued operations | 0.0 | 0.1 | 1.9 |
| Sales of subsidiaries | |||
| and associates' shares (net) | 0.0 | 2.8 | 2.8 |
| Purchase of PPE | -0.3 | -0.4 | -0.4 |
| Purchase of Intangible assets | -0.5 | -0.6 | -1.1 |
| NET CASH USED IN INVESTING ACTIVITIES | -0.8 | 1.8 | 1.3 |
| Cash flow from discontinued operations | 0.0 | 0.0 | 0.0 |
| Used options rights | 0.0 | 0.0 | 0.0 |
| Buyback of own shares | -0.2 | 0.0 | 0.0 |
|---|---|---|---|
| Paid dividends and repayments of capital | -5.6 | -3.6 | -3.6 |
| Repayments of long-term borrowings | -0.3 | -0.3 | -0.6 |
| Long-term loans received | 0.1 | 0.0 | 0.0 |
| Finance lease principal payment | 0.0 | 0.0 | 0.0 |
| NET CASH USED IN FINANCING ACTIVITIES | -5.9 | -3.8 | -4.1 |
| Cash flow from discontinued operations | 0.0 | 0.2 | 0.2 |
| Net change in cash and equivalents | -5.0 | 2.1 | 4.2 |
| Cash and equivalents. period-start | 8.3 | 4.1 | 4.1 |
| Cash and equivalents. period-end | 3.3 | 6.2 | 8.3 |
| Health Tech | Parent company | Group | ||
|---|---|---|---|---|
| Net sales 1-6/2016 | 11.0 | 0.0 | 11.0 | |
| Net sales 1-6/2015 | 9.5 | 0.0 | 9.5 | |
| Change (%) | 16 | 0 | 16 | |
| Segment profit margin 1-6/2016 | 3.7 | -0.7 | 3.0 | |
| Segment profit margin 1-6/2015 | 3.6 | -0.7 | 2.9 | |
| Change (%) | 4 | 7 | 3 |
| No. of shares | % | |
|---|---|---|
| 1. Joensuun Kauppa ja Kone Oy | 591,509 | 7 % |
| 2. Merivirta Jyri | 500,000 | 6 % |
| 3. Gerako Oy | 340,000 | 4 % |
| 4. Sijoitusrahasto Evli Suomi Pienyhtiöt | 282.546 | 4 % |
| 5. Keskinäinen Eläkevakuutusyhtiö Etera | 265,000 | 3 % |
| 6. Alpisalo Mia | 178,322 | 2 % |
| 7. Eyemakers Finland Oy | 155,000 | 2 % |
| 8. Sijoitusrahasto Danske Invest Suomen Pienyhtiöt | 125,000 | 2 % |
| 9. Sijoitusrahasto Evli Suomi Select | 119,818 | 2 % |
| 10. Salovaara Olli-Pekka | 104,207 | 1 % |
Revenio has adopted the guidelines of the European Securities and Market Authority (ESMA) on Alternative Performance Measures. In addition to the IFRS-based key figures, the company will publish certain other generally used key figures that may, as a rule, be derived from the profit and loss statement and balance sheet. The calculation of these figures is presented below. According to the company's view, these key figures supplement the profit and loss statement and balance sheet, providing a better picture of the company's financial performance and position.
| Earnings per share: | net profit for the period | ||
|---|---|---|---|
| Ξ | average number of shares during period | ||
| Equity per share: | equity attributable to shareholders | ||
| Ξ | number of shares at end of period | ||
| Average share price: | total EUR value of shares traded | ||
| $\equiv$ | total number of shares traded during period | ||
| Pre-tax profit-%: | $=$ | operating profit + financing income - financing expenses | |
| Return on equity-% (ROE): | 100 x profit for the financial period | ||
| $\equiv$ | shareholders' equity + non-controlling interest (average during period) | ||
| Return on investment-% (ROI): | 100 x profit before taxes + interest and other financial expenses | ||
| $\equiv$ | balance sheet total - non-interest-bearing debt (average during period | ||
| Equity ratio-%: | 100 x balance sheet equity + non-controlling interest | ||
| $\, =$ | balance sheet total - advance payments received | ||
| Net gearing-%: | $\equiv$ | 100 x interest-bearing debt - cash & equivalents | |
| total equity | |||
| Equity per share: | equity attributable to shareholders | ||
| Ξ | number of shares at end of period | ||
| Gearing-%: | 100 x interest-bearing net debt | ||
| Ξ | equity total |
This report contains certain statements that are estimates based on the management's best knowledge at the time they were made. For this reason, they involve a certain amount of inherent risk and uncertainty. The estimates may change in the event of significant changes in general economic conditions.
Revenio Group Corporation Board of Directors
For further information, please contact: Olli-Pekka Salovaara, President & CEO, tel +358 40 5675520 [email protected] www.revenio.fi
DISTRIBUTION: Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4 %. Revenio Group Corporation is listed on Nasdaq Helsinki.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.